CJC-1295 vs GHRP-6
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- GHRP-6 is the original synthetic GH-releasing peptide and a potent ghrelin receptor agonist. It produces strong GH pulses but is notorious for a significant hunger surge 30–45 minutes post-injection. This hunger side effect makes it less preferred than Ipamorelin or GHRP-2 for most protocols but can be useful in patients with appetite deficiency.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- 15–60 minutes
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 100 mcg
- 100–300 mcg
- Frequency
- Once daily, before bed
- 2–3 times daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Strong GH stimulation
- Elevated IGF-1
- Muscle growth and recovery support
- Potential anti-inflammatory effects at GI level
- Useful for patients with appetite deficiency or cachexia
- Enhanced recovery from training
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Intense hunger surge (30–45 min post-injection)
- Water retention
- Elevated cortisol (modest)
- Elevated prolactin (modest)
- +2 more
- Stacks With
- —
- —